NCT02147808已完成1 期
A Phase 1, Open-Label, Single-Center, 2-Period, Single-Sequence Drug-Drug Interaction Study to Evaluate the Effects of Multiple-Dose Telotristat Etiprate on the Pharmacokinetics of Single-Dose Midazolam, a Sensitive P450-3A4 Substrate, in Healthy Male and Female Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Midazolam plasma concentration in combination with steady state telotristat etiprate
研究概览
简要总结
This study is designed to evaluate the effects of telotristat ethyl on the pharmacokinetics of midazolam in healthy male and female subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult males and females ≥18 to ≤55 years of age at Screening.
- •Body mass index ≥18.0 to ≤2.0 kg/m^2
- •Acceptable vital signs at Screening: Systolic blood pressure = 90-140 mm Hg, Diastolic blood pressure = 50-90 mm Hg, Heart rate = 40-100 beats per minute
- •Willingness to adhere to the restrictions outlines in the protocol
- •Able to comprehend and sign the informed consent form.
排除标准
- •Presence of any clinically significant physical, laboratory, or ECG finding that may interfere with the study in the opinion of the Investigator
- •Use of any medications, herbal tea, energy drink, herbal products, or supplements
- •Receipt of any investigational agent or study drug within 30 days or 5 half-lives of study start
- •Receipt of any protein- or antibody-based therapeutic agent within 3 months of study start
- •Prior exposure to telotristat etiprate
- •Use of tobacco, smoking cessation products, or nicotine products within 3 months of study start
- •History of major surgery within 6 months of study start
- •History of acute narrow angle glaucoma
- •History of renal disease, or significantly abnormal glomerular filtration rate (<90 mL/min as calculated using the Cockcroft-Gault equation) at Screening
- •History of hepatic disease, or significantly abnormal liver function tests
- •History of any clinically significant psychiatric, renal, hepatic, pancreatic, cardiovascular, neurological, endocrinologic, hematological, or GI abnormality
- •History of any active infection within 14 days prior to first dosing
- •History of alcohol or substance abuse within 2 years prior to Screening
- •Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus antibody) or positive human immunodeficiency virus antibody screens
- •Concurrent conditions that could interfere with safety and/or tolerability measurements
- •Donation or loss of >500 mL of blood or blood product within 3 months
- •Women who are breastfeeding or are planning to become pregnant during the study
- •Positive serum pregnancy test (females only)
- •Positive urine screen for selected drugs of abuse and cotinine
- •Consumption of alcohol within 48 hours prior to study start
- •Consumption of caffeine- and/or xanthine-containing products
- •Consumption of grapefruit, Seville oranges, and grapefruit- or Seville orange-containing products within 72 hours prior to study start
- •Unable or unwilling to communicate or cooperate with the Investigator for any reason
- •Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of CYP3A4 within 30 days prior to the first dose
研究组 & 干预措施
All subjects
Experimental
All subjects will receive a single oral midazolam dose on Day 1 while fasting. Days 2 to 4 will be Washout days. On Day 5, subjects will begin a 5-day regimen of telotristat etiprate. On Day 9, subjects will receive a morning dose of telotristat etiprate with a single dose of midazolam while fasting.
干预措施: Telotristat etiprate (Drug)
All subjects
Experimental
All subjects will receive a single oral midazolam dose on Day 1 while fasting. Days 2 to 4 will be Washout days. On Day 5, subjects will begin a 5-day regimen of telotristat etiprate. On Day 9, subjects will receive a morning dose of telotristat etiprate with a single dose of midazolam while fasting.
干预措施: Midazolam (Drug)
结局指标
主要结局
Midazolam plasma concentration in combination with steady state telotristat etiprate
时间窗: Day 9
次要结局
- Number of treatment emergent adverse events(12 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy SubjectsDrug InteractionsNCT02157558Lexicon Pharmaceuticals24
已完成
1 期
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial SarcomaRhabdoid TumorsINI1-negative TumorsMalignant Rhabdoid Tumor of OvarySynovial SarcomaNCT02601937Epizyme, Inc.109
已完成
1 期
A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male SubjectsHealthy SubjectsNCT02841761Idorsia Pharmaceuticals Ltd.20
已完成
1 期
A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.HealthyNCT01756781Pfizer26
已完成
3 期
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)Bacterial InfectionsNCT02066402Bayer598